I don’t believe the stock moves on the first IV for Brazil because it’s expected . What will move the stock is some visibility into an accelerated enrollment for those 2:trials so people can do the math on what’s a realistic timeframe for an interim review. Also Breakthru designation will also move this stock, as would a jump in the Philippines revenue or that they have filed for an EUA there..But you can see the announcement on the university did zero today and I think the first IV won’t produce an upward movement.